{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-125484","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.998009+00:00","generated_at":"2026-05-20T15:18:03.948242+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sensei Biotherapeutics shareholders approve reverse stock split at 1:10-1:30 ratio","bullets":["Elected directors William Ringo (8.9M for) and John Celebi (9.2M for) to three-year terms.","Ratified Deloitte & Touche as independent auditor for FY2025: 15.8M for, 369.9K against.","Approved reverse stock split authorization (ratio 1:10 to 1:30) at board discretion; 14.7M for, 1.6M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-125484","json":"https://secwatch.observer/filing/0001193125-25-125484.json","markdown":"https://secwatch.observer/filing/0001193125-25-125484.md","text":"https://secwatch.observer/filing/0001193125-25-125484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/0001193125-25-125484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525125484/d13190d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T15:18:03.948242+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}